76
Participants
Start Date
May 21, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2027
SNDX-5613
Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
Chemotherapy Regimen
Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
HiDAC
Consolidation: Participants will receive HiDAC IV.
RECRUITING
The Alfred Hospital, Victoria, Melbourne
RECRUITING
Northern Hospital, Victoria, Epping
RECRUITING
Sir Charles Gairdner Hospital, Nedlands
RECRUITING
Hospital Clinic de Barcelona, Barcelona
RECRUITING
Hospital San Pedro de Alcantara, Cáceres
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
SUNY Upstate Medical University, Syracuse
RECRUITING
University of Rochester Medical Center, Rochester
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Hospital Universitario Virgen de Las Nieves, Granada
RECRUITING
West Virginia University, Morgantown
RECRUITING
Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
RECRUITING
Hospital General Universitario Gregorio Marañon, Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
MUSC Hollings Cancer Center (HCC), Charleston
RECRUITING
Emory Winship Cancer Institute, Atlanta
RECRUITING
AdventHealth Blood & Marrow Transplant Center, Orlando
RECRUITING
Tampa General Hospital, Tampa
RECRUITING
Hospital Universitario Marques de Valdecilla, Santander
RECRUITING
Norton Cancer Institute, St. Matthews Campus, Louisville
RECRUITING
Hospital Universitario Virgen del Rocio - PPDS, Seville
RECRUITING
Cleveland Clinic Foundation, Cleveland
RECRUITING
Universitat de Valencia, Valencia
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Allina Health Cancer Institute, Minneapolis
RECRUITING
University of Chicago, Chicago
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Baylor University Medical Center, Dallas
RECRUITING
The University of Texas, MD Anderson Cancer Center, Houston
RECRUITING
LDS Hospital - Intermountain Healthcare, Salt Lake City
RECRUITING
City of Hope Medical Center, Duarte
RECRUITING
UCLA Medical Hematology, Burbank
RECRUITING
Oregon Health and Science University- Center for Hematologic Malignancies, Portland
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
Hammersmith Hospital, London
RECRUITING
The Royal Marsden NHS, Sutton
Lead Sponsor
Syndax Pharmaceuticals
INDUSTRY